Compare
The details that actually shape the buying decision.
Evidence, risk, regulatory flags, cost, and vendor coverage — side by side, without affiliate spin.
01· Subject
Tirzepatide
Dual GIP/GLP-1 agonist with strong FDA-approved human data for glycemic control and weight loss.
Tier Amedium risk
02· Subject
CJC-1295
Long-acting GHRH analogue studied in human trials for sustained GH/IGF-1 elevation.
Tier Bhigh risk
01 · At a glance
| Decision factor | Tirzepatide | CJC-1295 | Tesamorelin |
|---|---|---|---|
| Primary fit | fat loss & metabolism research where you want a clear starting point | muscle growth & strength and fat loss & metabolism comparisons | fat loss & metabolism and gh axis optimization comparisons |
| Evidence | Tier A | Tier B | Tier A |
| Risk | medium | high | low |
| Experience level | intermediate | intermediate | advanced |
| Budget tier | premium | mid | premium |
| Administration route | subcutaneous | subcutaneous | subcutaneous |
02 · Use case & timing
| Decision factor | Tirzepatide | CJC-1295 | Tesamorelin |
|---|---|---|---|
| Goal fit | Fat Loss & Metabolism | Muscle Growth & Strength, Fat Loss & Metabolism, GH Axis Optimization | Fat Loss & Metabolism, GH Axis Optimization |
| What users compare it for | Large reductions in HbA1c and body weight in approved-use populations, with reduced appetite and improved metabolic markers. | Sustained GH and IGF-1 elevation; body composition modulation (long-horizon, not well-established for consumer outcomes). | Visceral fat reduction in HIV lipodystrophy (evidence-backed). General weight loss claims are limited. |
| Onset timeline | Metabolic effects begin within weeks; major body-composition changes accrue over months. | Biomarker effects persist multiple days; IGF-1 elevations up to ~2 weeks after single dose. | Clinical endpoints assessed at 26 weeks in pivotal studies. |
| Main tradeoff | Evidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter. | Evidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter. | Evidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter. |
03 · Safety & restrictions
| Decision factor | Tirzepatide | CJC-1295 | Tesamorelin |
|---|---|---|---|
| Adverse effects | GI intolerance is most common: nausea, vomiting, diarrhea, constipation, and appetite suppression. Gallbladder and pancreatitis concerns remain relevant. | Injection-site reactions, headache, diarrhea, flushing, transient hypotension at higher doses. | Increased neoplasm risk, elevated IGF-1, fluid retention, glucose intolerance/diabetes, hypersensitivity. |
| Contraindications | Avoid in personal or family history of medullary thyroid carcinoma or MEN2. Use caution with pancreatitis history, pregnancy, and other glucose-lowering drugs. | GH-axis stimulation risks: glucose intolerance, theoretical neoplasia concerns with elevated IGF-1. | Active malignancy, pregnancy, pituitary gland disorders (per label). |
| Interaction notes | Additive hypoglycemia risk with insulin or secretagogues. Delayed gastric emptying can affect oral-drug absorption timing. | Monitor insulin/glucose sensitivity, thyroid axis, and cortisol/prolactin. Trials report no significant cortisol/prolactin/TSH/LH increases at 60 µg/kg single dose. | CYP450-metabolized drugs; glucocorticoid replacement requirements may be affected. |
| Regulatory status | Prescription-approved | Not approved | Prescription-approved |
| FDA flag | FDA compounding caution | FDA compounding caution | No current flag noted |
| WADA status | Not listed | WADA S2 | WADA S2 |
04 · Age & monitoring
| Decision factor | Tirzepatide | CJC-1295 | Tesamorelin |
|---|---|---|---|
| Supported age ranges | 25-34, 35-44, 45-54, 55-64, 65+ | 25-34, 35-44, 45-54 | No age guidance yet |
| Life-stage note | Most relevant in adult metabolic-health and obesity contexts rather than early-life performance use. | Midlife is where GH-restoration framing is most often used, but evidence and long-term safety remain limited. | Not yet documented |
| Monitoring burden | medium | high | Not specified |
| Follow-up cadence | Early tolerance review, then periodic metabolic follow-up every few months. | Reassess at startup and then roughly every few months if continuing. | Not yet documented |
05 · Cost & sourcing
| Decision factor | Tirzepatide | CJC-1295 | Tesamorelin |
|---|---|---|---|
| Typical cycle cost | $200.00 | $143.98 | $600.00 |
| Estimated monthly cost | $200.00 | $47.99 | $600.00 |
| Cost confidence | Moderate confidence | High confidence | High confidence |
06 · Before you buy
| Decision factor | Tirzepatide | CJC-1295 | Tesamorelin |
|---|---|---|---|
| Tracked vendor listings | 1 listing | 3 listings | 3 listings |
| Sourcing note | Product format varies by listing, so double-check route, concentration, and presentation. | At least one listing is a blend rather than a clean standalone product, so review the product page carefully. | Tracked product pages exist, but naming differences mean the listing needs an extra read before purchase. |
| Stack-friendly? | Usually stack-friendly | Usually stack-friendly | Better as a standalone decision |
Still deciding
Get a plan tailored to you.
Side-by-side narrows the field. The quiz factors in your goal, experience, and risk tolerance to surface a starting compound and dosing range.